Prostaglandin analogues get the job done

August 20, 2007

Travoprost, latanoprost and bimatoprost all significantly reduce intraocular pressure (IOP) and increase ocular perfusion pressure (OPP) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), according to report published online ahead of print in Acta Ophthalmologica Scandinavica.

Travoprost, latanoprost and bimatoprost all significantly reduce intraocular pressure (IOP) and increase ocular perfusion pressure (OPP) in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT), according to report published online ahead of print in Acta Ophthalmologica Scandinavica.

Gurbuz Koz and colleagues from the Ankara Numube Education and Research Hospital, Ankara, Turkey enrolled 60 newly diagnosed patients and randomly assigned them to receive either travoprost 0.004% (n=12 with POAG, n=8 with OHT), latanoprost 0.005% (n=11 with POAG, n=9 with OHT) or bimatoprost 0.03% (n=13 with POAG, n=7 with OHT).

At six-months follow-up, IOP had decreased from 26.4±3.3 mmHg to 20.9±1.9 mmHg in the travoprost group, from 26.8±1.3 mmHg to 20.8±2.4 mmHg in the latanoprost group and from 25.8±1.8 mmHg to18.3±1.2 mmHg in the bimatoprost group. A significant increase in OPP was also seen in each group.

The authors of this study concluded that all three prostaglandin analogues are equally efficacious at reducing IOP and increasing OPP in POAG patients.